Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?

被引：412
作者：
Thota, Sreekanth [1 ,2 ]
Rodrigues, Daniel A. [2 ]
Crans, Debbie C. [3 ]
Barreiro, Eliezer J. [2 ]
机构：
[1] Fundacao Oswaldo Cruz, Minist Saude, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Av Brazil 4036,Predio Expansao,8 Andar, BR-21040361 Rio De Janeiro, RJ, Brazil
[2] Fed Univ Rio de Janeiro UFRJ, Inst Biomed Sci, Lab Avaliacao & Sintese Subst Bioat LASSBio, POB 68023, BR-21941902 Rio De Janeiro, RJ, Brazil
[3] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA
来源：
JOURNAL OF MEDICINAL CHEMISTRY | 2018年 / 61卷 / 14期
关键词：
RUTHENIUM(II) POLYPYRIDYL COMPLEXES; 2-PHOTON PHOTODYNAMIC THERAPY; NEGATIVE BREAST-CANCER; PROTEIN-KINASE INHIBITORS; DNA-BINDING; IN-VITRO; CELLULAR UPTAKE; SELENIUM NANOPARTICLES; MULTIDRUG-RESISTANCE; CYTOTOXIC ACTIVITIES;
D O I：
10.1021/acs.jmedchem.7b01689
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Metal based therapeutics are a precious class of drugs in oncology research that include examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and therapeutics applications. Ruthenium compounds have shown selective bioactivity and the ability to overcome the resistance that platinum-based therapeutics face, making them effective oncotherapeutic competitors in rational drug invention approaches. The development of antineoplastic ruthenium therapeutics is of particular interest because ruthenium containing complexes NAMI-A, KP1019, and KP1339 entered clinical trials and DW1/2 is in preclinical levels. The very robust, conformationally rigid organometallic Ru(II) compound DW1/2 is a protein kinase inhibitor and presents new Ru(II) compound designs as anticancer agents. Over the recent years, numerous strategies have been used to encapsulate Ru(II) derived compounds in a nanomaterial system, improving their targeting and delivery into neoplastic cells. A new photodynamic therapy based Ru(II) therapeutic, TLD1433, has also entered clinical trials. Ru(II)-based compounds can also be photosensitizers for photodynamic therapy, which has proven to be an effective new, alternative, and noninvasive oncotherapy modality.
引用
收藏
页码：5805 / 5821
页数：17
相关论文
共 149 条
[1]   Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy [J].
Abid, Mohammad ;
Shamsi, Farheen ;
Azam, Amir .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (10) :772-786
[2]   Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity [J].
Adhireksan, Zenita ;
Davey, Gabriela E. ;
Campomanes, Pablo ;
Groessl, Michael ;
Clavel, Catherine M. ;
Yu, Haojie ;
Nazarov, Alexey A. ;
Yeo, Charmian Hui Fang ;
Ang, Wee Han ;
Droege, Peter ;
Rothlisberger, Ursula ;
Dyson, Paul J. ;
Davey, Curt A. .
NATURE COMMUNICATIONS, 2014, 5
[3]   Ruthenium antimetastatic agents [J].
Alessio, E ;
Mestroni, G ;
Bergamo, A ;
Sava, G .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (15) :1525-1535
[4]   Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective [J].
Alessio, Enzo .
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2017, (12) :1549-1560
[5]  
Allardyce CS, 2001, PLATIN MET REV, V45, P62
[6]   Ruthenium-based chemotherapeutics: are they ready for prime time? [J].
Antonarakis, Emmanuel S. ;
Emadi, Ashkan .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) :1-9
[7]   Synthesis and DNA-binding studies of two ruthenium(II) complexes of an intercalating ligand [J].
Arockiasamy, D. Lawrence ;
Radhika, S. ;
Parthasarathi, R. ;
Nair, Balachandran Unni .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (05) :2044-2051
[8]   Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay [J].
Artner, Christian ;
Holtkamp, Hannah U. ;
Hartinger, Christian G. ;
Meier-Menches, Samuel M. .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2017, 177 :322-327
[9]   Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? [J].
Balasubramanian, Shankar ;
Hurley, Laurence H. ;
Neidle, Stephen .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (04) :261-275
[10]   Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates [J].
Bergamo, A. ;
Gaiddon, C. ;
Schellens, J. H. M. ;
Beijnen, J. H. ;
Sava, G. .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2012, 106 (01) :90-99
12345678910